The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Lupin’s double ‘A’ rating in Climate and Water exemplifies its steadfast commitment to sustainability
Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Subscribe To Our Newsletter & Stay Updated
